Laboratory medicine in pandemic of COVID-19Article Published on 2022-06-152023-07-08 Journal: Biochemia Medica [Category] COVID19(2023년), [키워드] COVID-19 GDF-15 Guillain-barrè syndrome infertility interleukin-6 [DOI] 10.11613/BM.2022.020501 PMC 바로가기
Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?COVID-19 관리를 위한 Artemisia 추출물 및 Artemisinin 기반 항말라리아제: 이것이 COVID-19 치료에 효과적인 항바이러스제일 수 있습니까?Review Published on 2022-06-142022-09-11 Journal: Molecules [Category] COVID19(2023년), SARS, 말라리아, 신약개발, 치료제, [키워드] active against acts acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Anti-inflammatory effects Antiviral Artemisia Artemisinin artemisinins combination therapies coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 demonstrated derivative derivatives Drug repurposing Effect Effectiveness Evidence exhibit Extract IL-6 Infection Inflammation inhibiting interleukin-6 Invasion lung damage malaria other diseases oxidative stress pandemic positive reducing Replication SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 severe COVID-19 shown Symptoms the SARS-CoV-2 treat Treatment [DOI] 10.3390/molecules27123828 PMC 바로가기 [Article Type] Review
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 SecretionIFN-β 및 IL-6 분비를 효율적으로 억제하기 위해 SARS-CoV-2 ORF6 단백질에 의해 핵공 이동이 방해됨Article Published on 2022-06-112022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] Activation addition antagonistic antiviral response block cascade characterized clinical outcomes contributing to counteract Critical cytokine Cytokines cytoplasm cytoplasmic demonstrated ENCODE exacerbated Factors feature Genes Host host immune system IFN-β IL-6 immune immune evasion Infection Inflammation interferon interferon antagonist interleukin interleukin-6 MAVS MDA-5 mechanism Messenger RNA movement mRNA multifunctional NF-κB not affected novel SARS-CoV-2 virus nuclear translocation nucleus occurred ORF6 pro-inflammatory cytokine pro-inflammatory cytokines Protein reported RIG-I SARS-CoV-2 SARS-CoV-2 ORF6 protein SARS-CoV-2 virus Signaling STAT suppresse suppression the SARS-CoV-2 Traffic transcription factor transcription factors transcriptional viral infection viral pathogenesis virulence virus [DOI] 10.3390/v14061273 PMC 바로가기 [Article Type] Article
Clinical characteristics and outcomes of COVID-19 patients in Bali, IndonesiaObservational Study Published on 2022-06-102022-10-05 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 임상, [키워드] Accuracy Admission Anosmia ANOVA C-reactive protein cause Characteristics clinical clinical feature Clinical symptoms collected conducted coronavirus disease cough COVID-19 COVID-19 patient COVID-19 patients diagnostic diagnostic value diagnostics Dyspnea eight evaluate Factor fatigue febrile Fever high accuracy hospitals illnesses Indonesia intensive care interleukin-6 Laboratory Lymphocyte count marker Non-COVID-19 non-COVID-19 patient offered outcome Patient radiologic severe cases severe COVID-19 severity Symptoms symptoms of COVID-19 these symptom ventilator were assessed with COVID-19 [DOI] 10.1371/journal.pone.0269026 PMC 바로가기 [Article Type] Observational Study
CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot StudyRandomized Controlled Trial Published on 2022-06-012022-10-04 Journal: Critical Care Medicine [Category] 임상, [키워드] 1:1 95% CI adjusted Adsorption adverse event age Antibiotics Berlin C-reactive protein clinical concentrations control group Controlled COVID-19 COVID-19 patient COVID-19 patients cytokine dose Effect Endpoint enrolled excluded Gender greater groups hazard ratio Hemodialysis ICU IMPROVE inflammatory markers interleukin-6 interquartile range IQR junction measurement median membrane Monmouth Mortality mortality rate Multiple one patient Patient pilot study primary endpoint Prospective Randomized receive reduction Registered registry rescue Resolution secondary Secondary endpoints Shock Standard of care Standard therapy study inclusion the primary endpoint treatment group university hospital variable Withdrawal [DOI] 10.1097/CCM.0000000000005493 PMC 바로가기 [Article Type] Randomized Controlled Trial
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study토실리주맙 치료를 받은 Sars-CoV-2 관련 중증 호흡 부전 환자의 나쁜 결과 예측자: 다기관 실제 세계 연구Multicenter Study Published on 2022-06-012022-09-12 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 진단, [키워드] Admission admitted to ICU age Analysis analyzed C-reactive protein (CRP CCT chest computer tomography composite endpoint COVID-19 creatinine death died Evidence Factor females Ground glass opacity Hospital admission ICU ICU admission IL-6 antagonist IMPROVE in-hospital mortality independent independent risk factor intensive care unit interleukin-6 intubation Laboratory lack lymphocyte material Mortality multicentre occurred Older outcome oxygen saturation P/F PaO2/FiO2 ratio Patient Pneumonia predictor procalcitonin Prognosis required respiratory Respiratory failure SARS-CoV-2 severe COVID-19 patients severe respiratory failure severe SARS-CoV-2 shown significantly significantly higher study population therapeutic option Tocilizumab tomography treated treated patient Univariate analysis [DOI] 10.1016/j.intimp.2022.108709 PMC 바로가기 [Article Type] Multicenter Study
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy Research Published on 2022-06-012022-10-05 Journal: Nature cancer [Category] 임상, 진단, 치료기술, 치료법, [키워드] 95% CI absence Adverse adverse event analyzed Cancer Cancer immunotherapy Cancer therapy clinically Cohort cohort study common condition COVID-19 vaccination COVID-19 vaccines CRS CXCL8 cytokine level Cytokine release syndrome Cytokines Diagnosis eight elevated event Hospitalized immune immune response immune-checkpoint inhibitor interleukin-6 modulate observé occurred Patient patients died receive response Serious Adverse Event serum serum cytokine single-center Symptoms therapy Treatment Tumor upregulated vaccination [DOI] 10.1038/s43018-022-00398-7 [Article Type] Research
Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19COVID-19에 대한 중간엽 줄기/기질 세포 기반 치료법: 살아있는 체계적인 검토 및 메타 분석의 첫 번째 반복: MSC 및 COVID-19Meta-Analysis Published on 2022-06-012022-09-11 Journal: Cytotherapy [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adherence adverse effects Analysis appear case sery Cell Cell-based therapy Clinical outcome Control coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria Critical determine Efficacy Endpoint estimate Exosomes Extracellular Extracellular vesicles Follow-up Future heterogeneity immunomodulatory interleukin-6 ISCT iteration Mesenchymal stem cells Mesenchymal stromal cells Meta-analysis Microvesicles moderate Mortality MSC MSCs nine not performed Other outcome Other outcomes pandemic patients patients with COVID-19 performed Pneumonia potential risk primary analysis random-effect random-effects repeated reported respiratory distress Respiratory distress syndrome risk risk of bia risk of death risk ratio RoB SARS-CoV-2 Secondary outcomes secreted Sepsis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 standardized mean difference Statistical power stromal cells Study design systematic review therapy for COVID-19 tissue repair treat [DOI] 10.1016/j.jcyt.2021.12.001 PMC 바로가기 [Article Type] Meta-Analysis
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3임상 데이터 마이닝은 IL-6/STAT3에 대한 이중 결합에 의해 중간 정도의 CovID-19에 대한 잠재적 인 허브 쌍으로 간카오-밴 내증을 밝혀냅니다.Article Published on 2022-06-012022-08-31 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 치료제, [키워드] activator Analysis applied association benzyl binding Bioinformatic Chinese Chinese medicines (CMs) clinical clinical records Commission coniferin coronavirus disease Coronavirus disease 2019 COVID-19 Critical cytokine Cytokine storm Data mining Defense demonstrated dual FIVE Frequency Gancao-Banxia Gene ontology genomes group highest IL-6 immune response immune responses indicated Inflammatory response ingredient inhibit interleukin interleukin-6 Interleukin-6 (IL-6) KEGG Kyoto licochalcone a Medicine Moderate COVID-19 moderate COVID-19 patients molecular docking multisite network network pharmacology Pathways patients piperazine potential mechanisms PPI protein-protein interaction provided quercetin quinone Radix reveal SARS-CoV-2 signal Signal transducer and activator of transcription Signal transducer and activator of transcription 3 (STAT3). signaling pathways STAT3 Support target targets the cytokine storm therapeutic efficacy therapy Transcription Viral were used [DOI] 10.1016/j.compbiomed.2022.105457 PMC 바로가기 [Article Type] Article
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study염증 표지자가 상승한 입원한 COVID-19 환자에서 토실리주맙의 조기 투여; COVIDSTORM-전향적, 무작위, 단일 센터, 공개 라벨 연구Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 바이오마커, 임상, 진단, [키워드] (interleukin-6 activities addition administration Admission benefit C-reactive protein clinical clinical recovery clinical status control group control patient control patients COVID-19 D-dimer demonstrated discharged elevated ferritin hospital Hospital admission Hospitalization Hospitalized hospitalized COVID-19 patient Hypoxemia immune response Inflammation inflammation markers Inflammatory inflammatory biomarkers intensive care intensive care unit admission interleukin interleukin-6 interquartile range marker median Open-label Ordinal Scale Patient patients hospitalized primary endpoint Randomized respiratory Respiratory Support SARS-CoV-2 secondary endpoint Secondary endpoints seven-category ordinal scale severe COVID-19 significantly SOC Standard of care TCZ Tocilizumab with COVID-19 [DOI] 10.1016/j.cmi.2022.02.027 PMC 바로가기 [Article Type] Randomized Controlled Trial